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Abstract 
AIM: To compare therapeutic responses of a vascular-disrupting-agent (VDA) Combretastatin-A4-
phosphate (CA4P) among hepatocellular carcinomas (HCCs) and implanted rhabdomyosarcoma (R1) 
in the same rats by magnetic-resonance-imaging (MRI), microangiography and histopathology. 
METHODS: Thirty-six HCCs were created by diethylnitrosamine gavaged in 14 rats that were also 
intrahepatically implanted with one R1 as monitored by T2-/T1-weighted images (T2WI/T1WI) on a 
3.0T MRI-scanner. Vascular response and tumoral necrosis were detected by dynamic-contrast-
enhanced (DCE-) and CE-MRI before, 1h and 12h after CA4P iv at 10 mg/kg (treatment group n=7) 
or PBS at 1.0 ml/kg (control group n=7). Tumor blood-supply was calculated by a semi-quantitative 
DCE parameter of area-under-the-time-signal-intensity-curve (AUC30). In vivo MRI findings were 
verified by postmortem techniques. 
RESULTS: On CE-T1WIs, unlike the negative response in all tumors of control animals, in 
treatment group CA4P caused rapid extensive vascular shutdown in all R1-tumors, but mildly or 
spottily in HCCs at 1h. Consequently tumor necrosis occurred massively in R1-tumors but patchily 
in HCCs at 12h. AUC30 revealed vascular closure (66%) in R1-tumors at 1h (P<0.05), followed by 
further perfusion decrease at 12h (P<0.01); while less significant vascular clogging occurred in 
HCCs. Histomorphologically, CA4P induced more extensive necrosis in R1-tumors (92.6%) than in 
HCCs (50.2%) (P<0.01); tumor vascularity heterogeneously scored +~+++ in HCCs but 
homogeneously scored ++ in R1-tumors. 
CONCLUSION: This study suggests superior performance of CA4P in metastatic over primary 
liver cancers, which could guide future clinical applications of VDAs. 
 
Key words vascular-disrupting agent (VDA); combretastatin A4 phosphate (CA4P); hepatocellular 
carcinoma (HCC); rhabdomyosarcoma (R1); magnetic resonance imaging (MRI); rats 
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Core tip: 
 Complex animal models combining primary and secondary liver malignancies proved feasible 
in rats.  
 The therapeutic efficacy of the leading vascular disrupting agent CA4P could be intra-
individually compared between primary and secondary liver malignancies in the same cirrhotic 
rats.  
 Clinical 3.0T MRI allowed real-time monitoring of in vivo therapeutic responses within 12 
hours, and ex vivo microangiography and histopathology could validate the CA4P-induced 
tumoricidal effects. 
 The therapeutic responses appeared superior with secondary liver tumors over that with primary 
HCCs, which are of translational significance for planning future clinical trials of CA4P in 
cancer patients. 
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Introduction 
As a first vascular disrupting agent (VDA), combretastatin A4 phosphate (CA4P) targets the 
cytoskeletal tubulin of the abnormal tumor endothelial cells, leading to a rapid but often reversible 
vascular occlusion [1-3]. Theoretically, this may cause ischemic tumor necrosis by depriving 
malignant cells from blood supply [1-3]. Clinically CA4P has been undergoing phase II/III trials in the 
setting of ovarian, thyroid and lung cancers alone or in combination with other chemotherapeutic 
agents [4-6], and a good safety profile has also been shown in the first phase I clinical trial among 
Chinese patient population [7]. In the majority of transplanted tumor models, CA4P consistently 
induced massive central tumor necrosis, leaving only a few layers of peripheral viable tumor cells 
culpable for the incomplete treatment and cancer relapse [8, 9], which is also attributed to the 
unsatisfactory clinical outcomes [3]. To tackle this bottleneck problem with all VDAs, a plausible 
solution has been proposed [10]. 
On the other hand, diverse and paradoxical tumor responses to CA4P have been recently noticed in a 
few preclinical studies based on a carcinogen-induced primary liver cancer model [11, 12]. By gavage 
administration of diethylnitrosamine (DENA) in rodents, multifocal hepatomas of a full spectrum of 
tumor vascularity and cellular differentiation superimposed on various degrees of liver cirrhosis 
could be generated [11-14]. Compared with the ectopically and orthotopically transplanted tumors, this 
primary HCC model is considered to be more clinically relevant for evaluating therapeutic drugs 
because of the heterogeneity in tumoral microenvironment similar to that of humans [13, 14], if an 
imaging platform can be available to accurately trace individual tumors [14, 15]. In this model CA4P 
simultaneously caused not only tumor necrosis but also reginal parenchymal necrosis in the cirrhotic 
liver [11, 12]. 
Tumor susceptibility to VDA therapy could be largely influenced by vascular features such as vessel 
density, diameter, reginal instabilities in blood flow, vascular permeability and interstitial fluid 
pressure (IFP) [16, 17]. Evidences have shown that, rather than larger tumor vessels, smaller or thinner 
ones are more susceptible to completely shut down in response to VDAs [11, 12, 17]. Apart from the 
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intrinsic properties of tumor vasculature, different tumor implantation sites and their dissimilar host-
organ blood-supplies may attribute to such variable efficacies of CA4P therapy as well [18, 19]. Take 
the ectopically implanted rhabdomyosarcoma (R1) as an example, intra-individual comparisons 
demonstrated that hepatic R1 tumors in the intact liver responded to CA4P much better than their 
subcutaneous and pancreatic counterparts did [18, 19].  However, issues still remain unknown as what 
if R1 tumors would grow in the cirrhotic liver, and whether R1 tumors growing in the cirrhotic liver 
are also good responders to CA4P as they presented in the normal liver [9, 10, 18-21]. 
So far experimentally on CA4P, all superior results in implanted liver tumors are derived from 
animals with healthy liver [9, 10, 18-21] and all inferior results on primary HCCs are from rats with liver 
cirrhosis [11]. Therefore, in order to assess this potential micro-environmental impact, it would be 
interesting to experimentally compare the therapeutic outcomes of CA4P between primary HCCs and 
secondary liver tumors in the same subjects with cirrhotic livers, though such a scenario is rarely 
seen in clinic [22]. Accordingly, in this study we employed a DENA-induced HCC model in WAG/Rij 
rats that received intrahepatic transplantation of a R1 tumor to intra-individually compare the 
responses of different tumors to CA4P administration under the same micro-environment of liver 
cirrhosis. A clinical 3.0T MRI was applied for in vivo real-time therapeutic monitoring within 12 
hours, while ex vivo microangiography and histopathology were performed to validate the CA4P-
induced outcomes.  
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Materials and Methods 
Animals and reagents 
Male Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats, which are syngeneic for the cell-line of 
rhabdomyosarcoma (R1), weighting 300-350 g were purchased from Charles River Breeding 
Laboratories, Inc. (St. Aubain les Elbeuf, France). Diethylnitrosamine (DENA, N0258) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Combretastatin A4 phosphate (CA4P, 
C643025) was procured from Toronto Research Chemical Inc. (Toronto, Canada). MRI contrast 
agent Dotarem® (Gd-DOTA, Gadoterate meglumine; Guerbet, France), barium sulfate suspension 
(Micropaque®, Guerbet, France) and gas anesthetic isoflurane (Forane®; Baxter Healthcare, 
Deerfield, IL) were also commercially obtained.  
Experimental design 
All animal experiments were approved by ethics committee of KU Leuven University and performed 
in compliance with European and national regulations. In vivo procedures including gavage feeding, 
drug injection and MR imaging were carried out under gas anesthesia with 2% isoflurane (Harvard 
Apparatus, Holliston, MA), while the laparotomy of intrahepatic R1 tumor implantation was carried 
out under general anesthesia with intraperitoneal injection of pentobarbital (Nembutal; Sanofi Sante 
Animale, Brussels, Belgium) at 50 mg/kg. 
As illustrated in Figure 1, multifocal primary hepatomas superimposed on liver cirrhosis were 
induced in rats by 14-week oral gavage of DENA at 5 mg/kg/day using a 16 cm-long flexible plastic 
esophageal gastric tube (Fuchigami Kikai, Kyoto, Japan) [13]. Tumor growth was monitored weekly 
by T2WI and T1WI from the 9th week until the largest liver tumor diameter reached more than 5 
mm. A R1 tumor tissue block of 1 mm3 was implanted into the lower part of medium liver lobe by 
laparotomy. Tumor growth was monitored weekly by MRI until R1 reached more than 5 mm in 
diameter. Next, all recruited tumor-carrying rats were randomly divided into sham group and CA4P 
group. Seven rats in CA4P group were intravenously injected with CA4P at 10 mg/kg, while the 
other 7 rats in sham group intravenously received phosphate buffered saline (PBS) at 1ml/kg. Multi- 
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parametric MRI was performed 4 h before and 1 h and 12 h post CA4P/PBS treatment. Rats were 
sacrificed immediately after the last time point of MRI scanning for postmortem microangiography 
and histopathology.  
In vivo MRI 
A clinical 3.0T scanner (MAGNETOM Prisma; Siemens, Erlangen, Germany) and a human wrist 
coil (Hand/Wrist 16, A 3T Tim coil, Siemens) were used for imaging acquisition. To monitor tumor 
growth, T2-weighted (repetition time, 4000 ms; echo time, 70 ms; flip angle, 150°; field of view, 
75×56 mm2; matrix, 256×192; and acquisition time, 3.4 min) and T1-weighted (repetition time, 626 
ms; echo time, 15 ms; flip angle, 160°; field of view, 75×56 mm2; matrix, 256×192; and acquisition 
time, 3.8 min) turbo spin echo (TSE) images (T2WI, T1WI) were performed weekly. Sixteen axial 
images with a slice thickness of 2.2 mm and a gap of 0.4 mm were acquired. To evaluate tumor 
responses to CA4P treatment, T2WI, T1WI, Dynamic contrast enhanced (DCE) and consecutive CE-
T1WIs were performed. DCE was conducted by a T1-weighted gradient echo (GE) sequence 
(repetition time, 7 ms; echo time, 2.45 ms; flip angle, 15°; field of view, 61×89 mm2; and matrix, 
132×192) with 60 measurements in total acquisition time of 7.3 min. During DCE, an intravenous 
bolus of 0.02 mmol/kg Gd-DOTA was injected after the first 17 precontrast baseline measurements 
that were continued with 43 postcontrast measurements. Then an intravenous bolus of 0.2 mmol/kg 
Gd-DOTA was injected, followed by consecutive CE-T1WI measurements. 
MR Imaging analyses 
Images were analyzed with an off-line Siemens workstation and MeVisLab (version 2.6.2, MeVis 
Medical Solutions AG, Bremen, Germany). All the following measurements were conducted by 3 
authors with consensus. 
1) Tumor diameter 
On T2WI, the tumor was manually contoured on the lesion-containing slices and tumor volume was 
automatically generated by the software, on which the tumor diameter was obtained. 
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2) Semi-quantitative analysis of T1-weighted DCE 
For DCE analysis namely AUC30 calculation, the operator-defined region of interest (ROI) of tumor 
was freehand delineated on all tumor-containing slices; ROI of abdominal aorta was delineated from 
4 consecutive slices for defining arterial input function; ROI of the liver was delineated on 4 
representative slices each from median, left, right and caudate lobes. All ROIs were automatically 
copied to all measurements. Because of a low gadolinium dose, a linear relation between the amount 
of contrast agent in the tissue and the resultant difference in relaxation time could been assumed [23]. 
As a robust semi-quantitative DCE parameter against movements, area under the time-signal 
intensity curve (AUC30) was calculated to reflect tumor blood flow [24].  
Digital microangiography   
After the last MRI scan, rats were anesthetized by an intraperitoneal injection of pentobarbital at 50 
mg/kg. A laparotomy was performed with abdominal aorta cannulated, through which barium 
suspension was injected before the entire tumor-bearing liver was excised. Postmortem hepatic 
arteriography was conducted by a digital mammography unit (Em-brace; Agfa-Gevaert, Mortsel, 
Belgium) at 26 kV and 32 mAs. Then the livers were fixed and sliced into 3-mm sections in the axial 
plane corresponding to the MR images, before being radiographed at 26 kV and 18 mAs for 
qualitative validation of tumor vascularity. 
Histopathology 
After microangiography, the tissue sections were paraffin-imbedded, sliced and stained with 
hematoxylin and eosin (H&E) for microscopic analyses using an Axiovert 200M microscope 
equipped with an AxioCam MR monochrome digital camera (Carl Zeiss Inc, Gottingen, Germany) 
and AxioVision 4.8 software. 
1) Calculation of CA4P-induced intratumoral necrosis 
Microscopic images of H&E stained tumor slices at a magnification of 12.5 were used to estimate 
the percentage of intratumoral necrosis by using ImageJ software [25]. To get ‘necrotic ratio on each 
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section’, ROIs around the entire tumor and the necrotic tumor were manually delineated, respectively. 
Sectional tumor area of each 3-mm tumor section was measured and represented as the axial slide 
representing this tumor block with the largest diameter. Tumor necrosis was estimated independently 
by 2 pathologists, and calculated with the equation: Intratumoral necrosis ratio (%) = ∑ [Necrotic 
ratio on each section (%) × section area (mm2)] × section thickness (mm) / [4/3π r3] (mm3). 
2) Grading of HCC differentiation  
In view of the high analogy to histopathological feature in human liver cancer, rat HCCs were 
diagnosed according to the classical histomorphologic features: malignant hepatocytic tumors, often 
well vascularized, with wide trabeculae (> 3 cell layers), noticeable acinar pattern, small cell changes, 
cytologic atypia, prominent nucleoli, mitotic activity, vascular invasion, absence of Kupffer cells, the 
lack of portal triad, and the loss of the reticulin network [26]. The differentiation of rat HCCs was 
further graded using a modified 4-scale Edmondson and Steiner system [26] as the standard criteria: 
grade I, highly differentiated, consisting of tumor cells of moderate size arranged in thin trabeculae; 
grade II, larger cells with active nuclear mitosis and possible pseudoglandular structures often with 
steatosis; grade III, larger nuclei and more hyperchromatic or increased mitotic figures, granular and 
acidophilic cytoplasm, often with giant tumor cells; and grade IV, much less differentiated tumor 
cells with hyperchromatic nuclei and loss of trabecular pattern often with angioinvasion [26]. 
3) Grading of tumor vascularity  
To characterize variable degrees of tumoral vascularity, a semi-quantitative vascular scoring system 
was adopted to classify HCCs as: (+) similar vascular density to the liver parenchyma; (++) dense 
vasculature without vascular lakes; (+++) denser vasculature with variously sized vascular lakes; and 
(++++) full of enlarged vascular lakes [11] [12].  
Statistical analyses 
Numerical data were expressed as the mean ± standard errors of the mean (SEM) and a significant 
difference was concluded for P<0.05. In vivo imaging biomarker AUC30 at different time points and 
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post-mortem tumoral necrosis were compared between HCC and liver R1 by unpaired two-tailed t-
test using GraphPad Prism (version 7.02, GraphPad Software Inc, La Jolla, CA, USA). 
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Results 
General aspects 
In general, all rats tolerated well the experimental procedures including gas anesthesia, DENA 
gavage, MRI scanning, laparotomy of intrahepatic tumor implantation, contrast administration and 
intravenous CA4P/PBS treatment. In total, 19 primary HCCs and 7 hepatic R1 allografts were 
successfully established in the 7 rats of CA4P group (Table 1), while 17 primary HCCs and 7 R1 
tumors were generated in the 7 rats of sham group. The rats were sacrificed 12 h after CA4P/PBS 
treatment when CA4P-induced tumor necrosis was most evident. 
Uniform vs. variable vascularity between hepatic R1 allografts and primary HCCs 
Similarly to the previous findings in Sprague Dawley (SD) rats [27], various tumoral vascularity and 
cellular differentiation of primary HCCs were discovered in WAG/Rij rats (Table 1). Yet vascularity 
of HCCs mainly appeared as grade +~++, probably due to a lower-dosed DENA gavage (5 mg vs. 10 
mg/kg/day) but a prolonged administration period (150 d vs. 90 d) in addition to the different species. 
In contrast, vascularity of intrahepatic R1 allografts was uniformly identified as grade ++ (Table 1), 
similar to that of other tumor studies on different animal strains [9, 10, 18-21]. 
Tumoricidal effects in metastatic R1 tumors vs. heterogeneous responses in primary HCCs 
In vivo real-time responses of primary HCCs and R1 allographs were visualized by multi-parametric 
MRI prior to, and 1 and 12 h post treatment. At baseline of CA4P group and all time points of sham 
group, hepatic R1 nodules appeared highly hyperintense on T2WIs (Fig. 2A1, 3A1, 2D1), iso- to 
slightly hyperinterse on precontrast T1WIs (Fig. 2A2, 3A2, 2D2) and homogeneously hyper-
enhanced on CE-T1WIs (Fig. 2A3, 3A3, 2D3) compared with the liver parenchyma. Additionally, 
spontaneous necrosis existing in hepatic R1 of Rat 3 was indicated by the unenhanced area on CE-
T1WI at baseline (Fig. 3A3). Intra-individually, their paired primary HCCs on the same imaging 
slice appeared moderately hyperintense on T2WIs (Fig. 2A1, 3A1, 2D1’) as well as on precontrast 
T1WIs (Fig. 2A2, 3A2, 2D2’), and hyper-enhanced on CE-T1WIs (Fig. 2A3, 3A3, 2D3’). 
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One hour after CA4P treatment, despite nearly unchanged intensities of hepatic R1 allographs on 
T2WIs (Fig. 2A1’, 3A1’) and T1WIs (Fig. 2A2’, 3A2’), signals on CE-T1WIs distinctly altered by 
an unenhanced central region surrounded by a positively enhanced periphery (Fig. 2A3’, 3A3’), 
indicative of ongoing extensive vascular shutdown. Nevertheless, the contrast of the primary HCC 
counterparts was slightly enhanced in a heterogeneous pattern (Fig. 2A3’, 3A3’). 
Twelve hours later, massive central necrosis occurred in all the hepatic R1 tumors, as reflected by 
extremely hyperintense on T2WIs (Fig. 2A1’’), isointense on T1WIs (Fig. 2A2’’, 3A2’’) and an 
unenhanced core surrounded by a hyperenhanced rim on CE-T1WIs (Fig. 2A3’’, 3A3’’). Meanwhile, 
By comparison, patchy necrosis was heterogeneously induced in primary HCCs, shown as generally 
increased hyperintensity on T2WIs (Fig. 2A1’’, 3A1’’), mingled hyper- and iso-intensities on T1WIs 
(Fig. 2A2’’, 3A2’’) and regional unenhancement scattering in extremely hyperenhanced lesions on 
CE-T1WIs (Fig. 2A3’’, 3A3’’).  
These in vivo imaging findings were eventually confirmed by postmortem microangiography and 
histopathology. At 12 h, complete absence of tumor vessels was particularly identified in the center 
of hepatic R1 (Fig. 2B, 3B), whereas in primary HCCs, generally denser vasculature was mixed with 
patchy avascular areas (Fig. 2B, 3B). From H&E stained slices, massive hemorrhagic necrosis and 
focal necrosis were indicated in hepatic R1 and in primary HCCs, respectively (Fig. 2C, 3C). 
Meanwhile, in the sham group (Fig. 2D), in vivo MRI did not show any obvious difference 4 h 
before, and 1 and 12 h after PBS injection. From postmortems, no vascular changes were 
microangiographically identified, and no acute tumoral necrosis was histopathologically discovered. 
Quantitative changes of tumor blood supply in correlation to CA4P-induced necrosis 
Real-time changes of tumor blood supply after CA4P administration were monitored by in vivo  
DCE-MRI. As reflected by AUC30 (Fig. 4A), blood flow in hepatic R1 tumors dropped by 66% at 1 
h due to vascular shut-down, followed by a further reduction of 7.3% at 12 h as a result of massive 
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tumoral necrosis (Fig. 4B). Nevertheless, in primary HCCs, only 11% tumor blood flow was reduced 
at 1 h because of vascular clogging, followed by a slight resume of tumor perfusion at 12 h (Fig. 4B), 
which was a heterogeneous combination of partial tumoral necrosis and re-opening of large 
intratumoral vessels in residual tumor. As validated by histopathological analysis, tumoral necrosis 
in liver R1 allographs (92.6%) was more extensive than that in primary HCCs (50.2%) at 12 h after 
CA4P treatment (Fig. 4C, Table 1). 
Taken together, these intraindividual comparisons demonstrated that in generally CA4P caused more 
extensive tumor vascular destruction and consequent tumoral necrosis in intrahepatically implanted 
R1 tumors than in the primary HCC lesions, both under the same cirrhotic liver background. 
Discussion 
To the best of our knowledge, this is the first study where 1) a rat tumor model combining primary 
HCCs and an implanted R1 tumor in the same cirrhotic liver has thus been established; and 2) the 
therapeutic efficacies of a VDA CA4P on distinct tumor types have been intra-individually compared. 
This, together with the applied MRI-microangiography-histology platform, could be regarded as 
methodological advances for conducting more efficient theragnostic investigations on spontaneous 
versus metastatic liver malignancies.  
This unique rat model of primary and secondary liver tumors induced by a carcinogen and surgery 
was employed not only to closely mimic the synchronous primary and metastatic liver malignancies 
seen in clinical patients, though of rarity [22], but also to better compare such complex liver cancers, 
especially in terms of different tumor differentiation, angiogenesis and vasculature, towards the same 
therapeutics of CA4P.  
Based on the fact that the target of CA4P is tumoral vasculature rather than cancer cells, transplanted 
R1 rhabodomyosarcoma is a suitable model of secondary hepatic tumor because of the similar tumor 
neovascularization process and the existing vasculature pattern to those intrahepatic metastases [15]. 
Transplanted R1 tumor is a type of homogeneous, hypervascularized, soild tumor, with abundant 
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micro-vessels[14]. Although in patients intrahepatic metastases occur via hematogenous route, they 
always end up with the same consequence of tumor neovascularization. Therefore, the derived 
results are representative of that in other metastatic liver tumors from different original sites.   
Unlike ectopically and orthotopically transplanted tumor models that yield reproducible outcomes, 
experimental models of primary liver malignancies tend to be more therapeutically and histologically 
unpredictable owing to intra- and intertumoral heterogeneity [11, 12]. Particularly, despite undergoing 
similar carcinogenesis, DENA-induced primary HCCs exhibit huge diversities in carcinoma 
development, neovascularization or tumor vascularity, microenvironment, and cellular differentiation 
in addition to varied degrees of liver cirrhosis [11, 12, 14]. Therefore, while constructing both primary 
and implanted tumors could be more time-consuming and technically challenging [13], this complex 
liver tumor model appears more clinically relevant for mimicking miscellaneous human cancers [14, 
22].  
In this study, distinct responses to CA4P, namely more complete tumoricidal effect on implanted R1 
tumors versus variable outcomes in primary HCCs, simultaneously occurred in the same rats with 
cirrhotic livers. These findings are in alignment with the previous studies conducted in either DENA-
induced primary HCC model on cirrhotic liver  [11, 12] or implanted R1 tumor model in normal liver [9, 
10, 20, 21]. Thus, the role of cirrhotic or normal liver background in the therapeutic impact of CA4P 
could be basically excluded. It was more likely that the intrinsic vasculature of the individual tumors 
eventually determined various outcomes of CA4P therapy. Indeed, as a widely accepted notion, 
implanted liver tumors resemble more closely to the secondary or metastatic liver cancer [15]. 
Therefore, our results strongly indicate that in general CA4P exerts more potent therapeutic effects 
on the metastatic liver tumors, rather than the primary liver tumors.    
In principle, tumor angiogenesis switches on when tumor reaches 1 mm3 in volume, since this is the 
limited size of diffusion within which solid tumor cells can grow [28]. Apart from the basic type of 
angiogenesis, namely endothelial sprouting, there are several nonangiogenic tumor vascularization 
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mechanisms including vasculogenic mimicry (VM), intussusception and vascular co-option [29, 30]. 
VM refers to tumor cells mimicking endothelial cells and directly participating in blood vessel 
formation, while intussusception and vascular co-option are both vascularization modes that 
essentially take advantage of the existing vasculature in the surrounding benign tissue [29, 30]. For 
instance, in experimental liver metastatic model produced by splenic injection of CD38 colon 
carcinoma cells in mice, enlarged sinusoidal lakes were discovered to be developed by fusion of the 
normal structure of sinusoids [31]. Since primary HCCs are generally hypervascularized tumors [32], 
vascularization based on remodeling the existing blood vessels is more complicated, especially in 
terms of enlarged vascular lakes. These evidences may to some extent explain the heterogeneous 
vasculature observed in our primary HCC model that developed gradually in the context of cirrhotic 
liver [11]. Supportively, by treating rats with DENA in a lower dose and a longer exposure period, less 
severe liver cirrhosis along with lower grades of tumor vascularity and HCC differentiation were 
identified in this study as compared to a previous study [11].  
Liver cirrhosis is considered as a precancerous condition since over 80% HCCs arise on a 
background of cirrhosis [26, 33]. In fact, the progression of cirrhosis is accompanied by a deformation 
of the hepatic vasculature in regenerated lobules [34]. Consequent hepatic vascular alterations include 
shunting of the portal and arterial blood directly into the central vein, compromising exchange 
between hepatic sinusoids and the adjacent liver parenchyma, and disturbed hepatobiliary excretion 
[32] [34]. In the context of cirrhosis, distorted neovasculature not only function as a unique mode of 
blood supply, but also appeared to be responsive to CA4P treatment, leading to patchy necrosis in 
cirrhotic liver paranchyma [12]. Hence, vigilance should be exercised when using VDAs upon patients 
with extensive liver cirrhosis, since acute necrosis in liver parenchyma could further impair hepatic 
function. 
Currently, although a series of phase II/III clinical trials have aimed at evaluating the treatment of 
CA4P in combination with chemotherapy in ovarian cancer [4], anaplastic thyroid cancer [5] and 
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nonsquamous non-small cell lung cancer patients [6], CA4P still literally remains an investigational 
medicine. The fetter that prevents CA4P from being ultimately adopted as a clinical anti-cancer 
therapy lies in tumor regrowth after monotherapy [35], despite its prompt, effective and generic 
responses in almost all solid tumors. Hence, combining CA4P with sequential treatments like 
chemotherapy, conventional radiotherapy, internal targeted radiotherapy and antiangiogenic therapy 
could reinvigorate these VDAs and provide better long-term outcomes. In fact, a dual-targeting pan-
anticancer theragnostic approach called OncoCiDia using CA4P sequentially with a radioiodinated 
necrosis avid compound 131I-Hypericin has been proposed to achieve CA4P-induced necrosis-
oriented internal targeted radiotherapy [10, 36]. In this context, prior to setting a serial VDA-centric 
anti-cancer protocols, the present synchronous multiple liver cancer model in rodents could be a 
stepping-stone to help predict the diverse responses that may occur in patients, and to further address 
more complicated clinically relevant questions [22]. For instance, to those patients with the HCCs less 
responsive to CA4P, alternatives such as radiofrequency ablation (RFA), microwave ablation (MW) 
and high intensity focused ultrasound (HIFU) can be applied to massively necrotize the tumor before 
systemic administration of a necrosis-avid radiopharmaceutical in the OncoCiDia strategy [10, 36]. 
 
Conclusions 
This study suggests distinct responses to CA4P, namely more complete tumoricidal effect on 
implanted R1 tumors versus variable outcomes in primary HCCs, simultaneously occurred in the 
same rats with cirrhotic livers, which could help to guide future clinical applications of VDAs. 
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Abbreviations 
CA4P: combretastatin A4 phosphate 
HCC: hepatocellular carcinoma  
MRI: magnetic resonance imaging 
DENA: diethylnitrosamine 
T2WI: T2-weighted imaging 
T1WI: T1-weighted imaging 
DCE- MRI: dynamic contrast enhanced MRI 
CE-MRI: contrast-enhanced MRI  
AUC30: area under the time-signal intensity 
curve 
VDA: vascular-disrupting agent 
IFP: interstitial fluid pressure 
WAG/Rij rats: Wistar Albino Glaxo/Rijswijk 
rats  
TSE: turbo spin echo turbo spin echo  
EPI: echo-planar imaging  
GE: gradient echo  
ROI: region of interest  
H&E: hematoxylin and eosin  
SEM: standard errors of the mean  
SD rats: Sprague Dawley rats 
VM: vasculogenic mimic
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ARTICLE HIGHLIGHTS 
Research background 
Previously, all favorable responses to the vascular-disrupting-agent (VDA) Combretastatin-A4-
phosphate (CA4P) on implanted liver tumors are derived from animals with healthy liver. Yet the 
diverse and paradoxical responses to CA4P on primary hepatomas are from rats with cirrhotic liver.  
 
Research motivation 
Therapeutic responses of CA4P between primary and secondary hepatic tumors had never been 
compared intraindividually in the same rats with underlying liver cirrhosis. And the potential micro-
environmental impact from the surrounding liver parenchyma needed to be further assessed.  
 
Research objectives 
We aimed to compare therapeutic responses of CA4P among carcinogen-induced primary 
hepatocellular carcinomas (HCCs) and surgically implanted rhabdomyosarcoma (R1) in the same 
rats by magnetic-resonance-imaging (MRI), microangiography and histopathology. 
 
Research methods  
We performed diethylnitrosamine (DENA) gavage to induce primary HCCs and meanwhile 
intrahepatic implantation of R1 to create secondary liver tumor in the same rats. Tumor growth was 
monitored by T2-/T1-weighted images on a 3.0T MRI-scanner. Rats were then intravenously treated 
with CA4P. Vascular response and tumoral necrosis before and after treatment were compared by 
dynamic-contrast-enhanced (DCE-) and CE-MRI. Tumor blood supply was further calculated by a 
semi-quantitative DCE parameter of area-under-the-time-signal-intensity-curve (AUC30). 
Eventually in vivo MR imaging findings were validated by postmortem techniques. 
 
Research results  
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In total, 19 primary HCCs and 7 hepatic R1 allografts were successfully established in the 7 rats of 
CA4P group, while 17 primary HCCs and 7 R1 tumors were generated in the 7 rats of sham group. 
Uniform and variable vascularity were identified, respectively, in hepatic R1 allografts and primary 
HCCs. As documented by in vivo MRI and post-mortem histopathology, vascular shutdown 
generally occurred at 1 hour after CA4P treatment; 12 hours later, tumoricidal effects were observed 
in secondary R1 tumors, while heterogeneous responses were seen in the primary HCCs. 
Quantitatively, tumor blood supply reflected by AUC30 showed vascular closure (66%) in R1-
tumors at 1h (P<0.05), followed by further perfusion decrease at 12h (P<0.01); while less significant 
vascular clogging occurred in HCCs. Histomorphologically, CA4P induced more extensive necrosis 
in R1-tumors (92.6%) than in HCCs (50.2%) (P<0.01); tumor vascularity heterogeneously scored 
+~+++ in HCCs but homogeneously scored ++ in R1-tumors. 
 
Research conclusions  
To verify our original hypothesis that primary and secondary liver cancers may respond differently to 
VDA therapy due to the dissimilar tumor vascularity, a complex rat tumor model combining 
carcinogen-induced primary HCCs and a surgically implanted R1 tumor in the same cirrhotic rats has 
thus been established to compare CA4P therapeutic responses intraindividually under the same 
micro-environment. Indeed, our hypothesis was verified by the superior performance of CA4P in 
metastatic over primary liver cancers. This could help to design future clinical trials and guide 
applications of VDAs. 
 
Research perspectives  
The merit of this study is that the present synchronous multiple liver cancer model in rodents could 
be a stepping-stone to help predict the diverse responses that may occur in patients, and to further 
address more complicated clinically relevant questions. The lesson that could be learnt from this 
study lies in, although HCCs are generally hypervascularized, we should not take it for granted that 
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the rich abnormal blood vessels naturally serve as plenty of drug targets for the VDA to inevitably 
induce massive tumor necrosis. This preclinical study is for preparing a novel dual targeting pan-
anticancer theragnostic strategy OncoCiDia in human liver cancers where CA4P could be applied as 
the first step. 
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Table 1. Intra-individual comparison of induced tumor necrosis (%) between primary HCCs 
and intrahepatically implanted R1 rhabdomyosarcomas in CA4P-treated group 
Note: 
* A vascular scoring system for rat liver tumor: vascular density similar to that of liver parenchyma 
(+), denser vasculature without vascular lakes (++), denser vasculature with small-sized vascular 
lakes (+++), and full of large vascular lakes (++++). 
** A 4-scale grading system for HCC differentiation in rats: well (I), moderately (II), poorly (III) and 
un-(IV) differentiated HCC lesions. 
*** Tumor vascularity was graded as + in the necrotic tumor, and +++ in the residual viable part. 
**** HCC differentiation was scored by I in the necrotic tumor, and III in the residual viable part.  
 Primary HCC Implanted hepatic R1 
Rat 
Tumor 
code 
CA4P-
induced 
necrosis 
(%) 
Tumor 
diameter 
(mm) 
Tumor 
vascularity
* 
Tumor 
differentiation
** 
Tumor  
code 
CA4P-
induced 
necrosis 
(%) 
Tumor 
diameter 
(mm) 
Tumor 
vascularity 
* 
1 
HCC_1 21.8 9.7 ++ II 
R1_1 72.3 12.1 ++ HCC_2 16.4 6.5 ++ III~IV 
HCC_3 0 10.9 ++ III 
2 
HCC_4 43.1 6.4 + III 
R1_2 84.5 12.6 ++ 
HCC_5 23.3 8.5 ++ III 
3 
HCC_6 92.3 8.1 + * I~II 
R1_3 99.2 10 ++ 
HCC_7 96.5 6.2 + * II 
HCC_8 19.8 10 + I 
HCC_9 98.9 10 + II 
4 HCC_10 99.2 14.3 + * I~II R1_4 96.8 9.8 ++ 
5 
HCC_11 27.6 18.3 + III 
R1_5 99.4 8.3 ++ HCC_12 4.9 7.8 ++ II~III 
HCC_13 62.7 13 + I~II 
6 
HCC_14 47.6 14.2 +, +++ *** I, III **** 
R1_6 97.7 9 ++ 
HCC_15 46.4 14.2 +, +++ *** I, III **** 
7 
HCC_16 76.1 12.5 + * II~III 
R1_7 98.3 6.2 ++ 
HCC_17 52.6 11.9 + III 
HCC_18 33.4 10.4 + III 
HCC_19 91.2 9 + * I~II 
Mean ± SD 50.2 ± 1.8 10.6 ± 0.2 / /  92.6 ± 1.5 9.7 ± 0.3 / 
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Figures and Figure Legends 
Figure 1. Flow chart of experimental protocol. DENA: diethylnitrosamine; WAG/Rij rat: Wistar 
Albino Glaxo/Rijswijk rat; MRI: magnetic resonance imaging; T2WI: T2-weighted imaging; T1WI: 
T1-weighted imaging; HCC: hepatocellular carcinoma; Ø: diameter; R1: R1 rhabdomyosarcoma; 
PBS: phosphate buffered saline; CA4P: combretastatin A4 phosphate; iv: intravenous(ly); h: hour; 
DCE: dynamic contrast enhanced; CE: contrast-enhanced. 
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Figure 2. Intra-individual comparison of therapeutic responses to CA4P between a primary 
HCC and a hepatic R1 allograft located in different liver lobes. (A) T2WIs (1-1’’), T1WIs (2-2’) 
and CE-T1WIs (3-3’’) of an implanted R1 tumor (green arrows) and a primary HCC (orange arrows) 
located in the median and left liver lobes, respectively, at baseline and 1 h and 12 h post CA4P 
therapy. (B) Corresponding photomacrographs of median and left liver lobes (top panels), 
photomacrograph of liver blocks (median panel) in 2-mm thickness corresponding to the transversal 
MR images, and microangiogram (bottom panel) of tumor-bearing liver blocks, revealing 1 R1 
tumor (green circle) and 1 primary HCC (orange circle). (C) Corresponding photomicrographs of R1 
tumor (left column) and primary HCC (right column) in the median and left lobes, respectively. 
(H&E staining; upper panels, ×12.5 original magnification, scale bar = 800 μm; lower panels, ×100 
original magnification, scale bar = 100 μm, ×400 original magnification, scale bar = 25 μm. N: 
tumoral necrosis; L: liver; viable tumor.). (D) Sham control: T2WIs (1, 1’), T1WIs (2, 2’) and CE-
T1WIs (3, 3’) of R1 tumor (green arrows) and primary HCC (orange arrows) located in the median 
and left liver lobes, respectively, at 12 h post PBS treatment; and corresponding photomicrographs (4, 
4’; H&E staining ×100 original magnification, scale bar = 100 μm, ×400 original magnification, 
scale bar = 25 μm. T: viable tumor; L: liver). 
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Figure 3. Intra-individual comparison of therapeutic responses to CA4P between a primary 
HCC and a hepatic R1 allograft distributed in the same liver lobe. (A) T2WIs (1-1’’), T1WIs (2-
2’’) and CE-T1WIs (3-3’’) of an implanted R1 tumor (green arrows) and a primary HCC (orange 
arrows) both located in the same left liver lobe at baseline and 1 h and 12 h post CA4P therapy. (B) 
Corresponding macroscopic photographs of the left liver lobe (top panel) and liver blocks (median 
panels) in 2-mm thickness corresponding to the transversal MR images, and microangiograms 
(bottom panels) of tumor-bearing liver block, revealing a R1 tumor (green circle) and a primary HCC 
(orange circle). (C) Corresponding photomicrographs of R1 tumor (left column) and primary HCC 
(right column). (H&E staining; upper panels, ×12.5 original magnification, scale bar = 800 μm; 
lower panels, ×100 original magnification, scale bar = 100 μm, ×400 original magnification, scale 
bar = 25 μm. L: liver; T: viable tumor; N: tumoral necrosis.). 
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Figure 4. Changes of semi-quantitative DCE parameter of primary HCCs and implanted liver 
R1 tumors and quantification of CA4P-induced tumoral necrosis. (A) Representative contrast 
enhancement-time curves (CTCs) of a primary HCC and a secondary liver R1 tumo before, 1 and 12 
h after CA4P treatment, for calculating tumor AUC30 at different time points. (B) Quantitative 
changes of tumor blood supply between HCCs and R1 tumors at baseline and 1 h and 12 h post 
CA4P treatment indicated by AUC30. (C) Bar chart compared the percentile tumoral necrosis 
between primary HCCs and implanted liver R1 at 12 h post CA4P therapy, which was estimated by 
post-mortem H&E staining (**P<0.01).  
